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Introduction: The corneal stroma is being increasingly recognized as a repository for stem cells. Like the limbal and
endothelial niches, stromal stem cells often reside in the peripheral cornea and limbus. These peripheral and limbal
corneal stromal cells (PLCSCs) are known to produce mesenchymal stem cells in vitro. Recently, a common corneal
stromal and epithelial progenitor was hinted at. This study aims to examine the stem cell potential of corneal
stromal cells and to investigate their epithelial transdifferentiation ability.
Methods: PLCSCs were grown in traditional Dulbecco modified Eagle medium (DMEM)-based keratocyte culture
medium and an M199-based medium and analyzed for a profile of cell-surface markers by using flow cytometry
and differentiated into mesenchymal phenotypes analyzed with quantitative polymerase chain reaction (qPCR) and
histologic staining. PLCSCs in M199 were subsequently divided into subpopulations based on CD34 and CD105
expression by using fluorescence- activated cell sorting (FACS). Subpopulations were characterized by marker profile
and mesenchymal differentiation ability. Both whole PLCSCs and subpopulations were also cultured for epithelial
transdifferentiation.
Results: Cells cultured in M199 demonstrated a more stem-like cell-surface marker profile, and the keratocyte
marker CD34 was retained for several passages but absent in cells cultured in DMEM. Cells cultured in M199 also
exhibited a greater mesenchymal differentiation potential, compared with DMEM. PLCSCs could be divided into
CD34+CD105+, CD34-CD105+, and CD34-CD105- subpopulations, of which CD34+CD105+ cells were the most
stemlike with regard to marker expression and mesenchymal differentiation potential. Subpopulations of PLCSCs
exhibited differing abilities to transdifferentiate into epithelial phenotypes. Cells that were initially CD34+CD105+
showed the greatest differentiation potential, producing CK3+ and CK19+ cells, and expressed a range of both
epithelial progenitor (HES1, FRZB1, DCT, SOD2, ABCG2, CDH1, KRT19) and terminally differentiated (DSG3, KRT3, KRT12,
KRT24) genes.
Conclusions: Culture medium has a significant effect on the phenotype and differentiation capacity of PLCSCs. The
stroma contains a heterogeneous cell population in which we have identified CD34+ cells as a stem cell population
with a capacity for mesenchymal and epithelial differentiation.
Keywords: Corneal stroma, Corneal epithelium, Mesenchymal stromal cells, Cell transdifferentiation, CD34,
Epithelial-mesenchymal transition* Correspondence: andrew.hopkinson@nottingham.ac.uk
†Equal contributors
The Division of Ophthalmology and Visual Sciences, Queen’s Medical Centre
Campus, University of Nottingham, Nottingham, UK
© 2013 Hashmani et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Hashmani et al. Stem Cell Research & Therapy 2013, 4:75 Page 2 of 13
http://stemcellres.com/content/4/3/75Introduction
Corneal blindness is a leading worldwide cause of treat-
able vision loss [1]. Trauma to the cornea can occur
from a wide range of environmental factors, including
chemical and thermal burns, mechanical and surgical
trauma, or microbial infection [2,3]. Specialized cellular
and structural organization is essential for the corneal
transparency required for effective vision [4-7]; the cor-
nea poses unique therapeutic challenges. Donor short-
ages and problems with immune rejection have
propelled the development of regenerative medicine
strategies for the cornea. Current and potential treat-
ments are diverse; approaches include partial or total
corneal replacements, the use of cellular or acellular
constructs, and synthetic or biologic materials [8-12].
The corneal stem cell niche is located at the limbus,
the boundary of the cornea, and contains both corneal
epithelial [13,14] and stromal stem cells [15-18]. How-
ever, the term limbal stem cells (LSCs) is applied exclu-
sively to the corneal epithelial progenitors. LSC
transplantation is used routinely to treat epithelial defi-
ciencies in the cornea [3,9,19]. This can involve direct
transplantation of limbal tissue for in situ epithelial re-
generation, or indirect transplantation of ex vivo ex-
panded sheets of replacement cells [3,9,20]. Both
treatment strategies can comprise autologous [4,9,20] or
allogeneic [19] material.
Corneal and limbal epithelium is supported by a mes-
enchymal stroma [21,22], which contains cells conven-
tionally known as keratocytes. Keratocytes normally
remain quiescent [23,24] and exhibit a dendritic morph-
ology with extensive cellular contacts [25,26]. These cells
maintain corneal stromal transparency at a structural
level by producing collagen lamellae and proteoglycans,
including keratocan, decorin, lumican, and mimecan
[23,27-34]. At the intracellular level, transparency is
aided by the production of crystallins, aldehyde dehydro-
genase class 1 (ALDH1) and transketolase [35-37].
These characteristic proteins can be used to identify
keratocytes, along with cell-surface markers CD133 and
CD34 [24,38,39].
The perception of keratocytes and their role within the
corneal and limbal stroma is shifting as other properties
are being attributed to them. Recently, we demonstrated
that cultured stromal cells of the limbus and peripheral
cornea (PLCSCs), produce a mesenchymal stem cell
(MSC) population [15], as described by the International
Society for Cellular Therapy (ISCT) [40]. Subsequent
research on these MSCs has shown that they may pro-
vide a supportive niche for epithelial stem cells [41],
similar to the role of MSCs in bone marrow [42,43],
and that they possess the immunosuppressive proper-
ties demonstrated by MSCs from other sources [44].
Bray et al. [45] found the typical keratocyte cultureconditions of Dulbecco modified Eagle medium (DMEM),
supplemented with 10% fetal bovine serum (FBS), pro-
duced suboptimal culture conditions for MSCs, and that
other media types may generate a more stemlike pheno-
type. What remains uncertain is whether the cell-culture
medium produces a change in cellular phenotype, or if
specific subpopulations present in PLCSCs are favored in
different media.
Although the use of corneal stromal stem cells in cor-
neal regeneration is less established than that of LSCs,
increasing evidence suggests an effectiveness in this area,
particularly in innovative tissue-engineering strategies
[46-48]. PLCSCs may therefore play a direct role in
the provision of cells for corneal maintenance and re-
generation. Within PLCSCs, CD34+ keratocytes are of
particular interest, as increasing evidence suggests an
association between the expression of CD34 and a com-
mon mesenchymal/epithelial progenitor in other tissues
[49-51]. MSC-epithelial transdifferentiation also has been
reported [52-55], and CD34 is commonly used as a
marker of skin epithelial progenitors that reside in the
stroma of the dermis [56-58]. Therefore, mesenchyme-
derived limbal stromal progenitors may play a role in cor-
neal epithelial regeneration. In support of this, we recently
published evidence that suggests that CD34+ keratocytes
spontaneously co-express the corneal epithelial marker
cytokeratin (CK) 3 [59].
Herein, we compare the stem cell phenotype of
PLCSCs in our previously published culture conditions
[15] with those cultured in the traditional keratocyte
medium and show that despite its widespread use and
lower serum content, the keratocyte medium is inferior
at maintaining an MSC phenotype. We also demonstrate
the heterogeneity of PLCSCs by isolating distinct sub-
populations, including CD34+ keratocytes. We then es-
tablish that the CD34+ subpopulation shows enhanced
epithelial transdifferentiation in comparison to the other
subpopulations.
Materials and methods
Isolation of peripheral and limbal corneal stromal cells
Use of human donor tissue for research was approved
by the local ethics research committee (NRES Commit-
tee East Midlands-Nottingham 1, 07/H0403/140). and
in accordance with the tenets of the declaration of
Helsinki, after consent obtained from the donors or their
relatives.
PLCSCs were isolated from corneal rims, as previously
described [15,60]. In brief, the epithelial and endothelial
layers were removed by mechanical scraping, and the re-
mainder of the limbus/tissue was cut into small pieces
and digested in 0.1 mg/ml collagenase type IA (Sigma
Aldrich, Dorset, Gillingham, UK). The tissue was incu-
bated for approximately 18 hours at 37.0°C, 5% CO2,
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(Fisher Scientific, Leicestershire, UK) to remove debris.
Culture medium was added to the collagenase filtrate
solution before centrifugation at 450 g for 6 minutes.
The supernatant was decanted, and the cell pellet
resuspended in the appropriate culture medium.Cell culture
PLCSCs were cultured in one of two culture media. First
was a standard keratocyte medium (KM), [17,46]
consisting of DMEM (Gibco, Invitrogen, Paisley, UK),
supplemented with 10% vol/vol heat-inactivated FBS
(Fisher Scientific), 0.02 μg/ml gentamicin, 0.5 ng/ml
amphotericin B (Gibco), 4.5 μg/ml insulin, human re-
combinant (Gibco), and 0.5% vol/vol DMSO (Sigma
Aldrich). The second was a medium previously shown
to support the expansion of MSCs [15, 61-63] (MM),
consisting of M199 medium (Sigma) supplemented with
20% vol/vol heat-inactivated FBS, 2.5 μg/ml antibiotic
solution, Plasmocin (Autogen Bioclear, Wiltshire, UK),
0.02 μg/ml gentamicin, 0.5 ng/ml amphotericin B
(Gibco), and 1.59 mM L-glutamine (Sigma Aldrich).
All extracted PLCSCs were initially cultured in 25 cm2
culture flasks (Fisher Scientific); this was considered to
be passage 0 (P0), and the medium was changed every 2
days. Cells were passaged at 80% confluence at a 1:3 ra-
tio, as previously described [15].Sample preparation for flow-cytometry analysis and cell
sorting
PLCSCs and subpopulations were prepared, analyzed,
and sorted by using protocols previously described [15].
In brief, cells for analysis were suspended in phosphate-
buffered saline (PBS) and fixed by using 3% vol/vol
formaldehyde (Sigma Aldrich) for 5 minutes and subse-
quently washed. PLCSCs for sorting were suspended in
a minimal volume of corresponding culture medium.
Cells were then incubated with the appropriate primary
conjugated antibodies for 30 minutes, washed, and
resuspended. PLCSCs were analyzed by using the Epics
Altra Flow Cytometer (Beckman Coulter, London, UK).
Antibodies were as follows: CD11b, CD13, CD19, CD29,
CD34, CD44, CD45, CD49b, CD49d, CD49e, CD105,
HLA-ABC, and HLA-DR (Beckman Coulter), CD49f,
CD104, CD106, and cytokeratin 14 (AbD Serotec,
Oxford, UK), CD73 (R&D Systems, Foster City, CA,
USA), CD90 (BD Pharmingen, Oxford, UK), CD133/2,
and CD271 (Miltenyi Biotec, Surrey, UK), ABCG2 (Santa
Cruz, Middlesex, UK), Stro-1 (Biolegend, Cambridge,
UK), Keratin 3/76 (CK3; Millipore, Fisher Scientific),
Cytokeratin 14 (CK14, AbD Serotec), Cytokeratin 19
(CK19), vimentin (Abcam, UK), and ABCG2 (Santa
Cruz, UK).PLCSCs were sorted between P0 and P1 by using
FACS with a MoFlo XDP Cell Sorter (Beckman Coulter).
After FACS, subpopulations were cultured for a further
three passages for cell-surface marker (CSM) analysis
and differentiation. Postanalysis data were plotted by
using WEASEL version 3.0, as previously described [15].
Isotype controls were used as negative controls, and the
threshold set to 0.5% for the percentage of positive cells.
Differentiation and histologic staining
PLCSCs were seeded at a density of 1.04 × 104 cells/cm2
in six-well plates at P3 and differentiated into adipogenic,
chondrogenic, or osteogenic differentiation medium,
for 21 days, as previously described [15,64]. Cells were
stained with Oil Red O (Sigma Aldrich), Alcian blue
(HD Supplies, UK), and Alizarin red (Sigma Aldrich)
for adipogenic, chondrogenic, and osteogenic differen-
tiation, respectively. Cells were visualized under an
inverted light microscope (Nikon Eclipse TS100 Light
Microscope, Japan), and images captured with a digital
camera (Nikon D70s).
Epithelial transdifferentiation
FACS-isolated subpopulations were seeded at a density
of 1.04 × 104 cells/cm2 and cultured in MM. At 90%
confluence, MM was switched to CnT-20 medium
(CellnTec Advanced Cell Systems, Switzerland). Nega-
tive controls were maintained in MM and cultured
alongside. Culture medium was changed every 2 days,
and cells were cultured for 14 days. Cells were imaged
under a light microscope, as previously described [15].
RNA extraction, cDNA synthesis, and quantitative PCR
RNA was isolated from cells by using the RNeasy Mini
Kit (Qiagen, UK), and each sample was analyzed in trip-
licate in accordance with the manufacturer’s protocol: 1
ng/μl of extracted RNA was used for cDNA synthesis by
using the QuantiTect Reverse Transcription Kit (Qiagen,
UK) according to the manufacturer’s protocol.
Inventoried Taqman assays (Applied Biosystems,
Warrington, UK) were used for the genes as follows:
adipogenesis, fatty acid synthase (FASN), perilipin
(PLIN) and peroxisome proliferator-activated receptor
gamma (PPARG); chondrogenesis, cartilage oligomeric
matrix protein (COMP), aggrecan (ACAN), and Sry-
related HMG box 9 (SOX-9); and osteogenesis, bone
morphogenetic protein 4 (BMP4), bone morphogenetic
protein 6 (BMP6), and osteoclastogenesis inhibitory fac-
tor (OPG). Corneal epithelial progenitor genes; hairy and
enhancer of split 1 (Drosophila), (HES1), frizzled-related
protein (FRZB1), dopachrometautomerase (dopachrome
delta-isomerase, tyrosine-related protein 2) (DCT),
superoxide dismutase 2, mitochondrial (SOD2), ATP-
binding cassette, subfamily G member 2 (ABCG2), E-
Figure 1 Effect of culture medium on percentage of PLCSCs
expressing CD105 and CD34. PLCSCs were cultured in either KM
or MM, for up to nine passages. At each passage, cells were
analyzed with flow cytometry for the presence of CD34 and CD105.
Values are represented as mean ± SD; flow cytometry was
performed on three separate donor-cell populations.
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(KRT19). Differentiated corneal epithelial genes; keratin
3 (KRT3), keratin 12 (KRT12), keratin 24 (KRT24),
desmoglein 3 (DSG3). Housekeeping gene; 18S rRNA.
Amplification was performed by using the Mx2005P
multicolor 96-well PCR system (Stratagene, Agilent
Technologies, Cheshire, UK) with parameters of 95°C
for 10 minutes) followed by 40 cycles of 95°C for 30 sec-
onds, 55°C for 1 minute, and 72°C for 30 seconds. Data
analysis was performed by using MxPro software, ver-
sion 4.2 (Stratagene, UK) to measure the threshold cycle
(Ct) for each reaction. The mean Ct value was
established by using triplicate Ct values, and analysis was
completed by using the ΔΔCt method [65].
Results
Cell-surface marker expression
Initially, the PLCSCs were cultured in either KM or MM,
and the expression of CD105 and CD34 were analyzed
by using flow cytometry at each passage, up to passage 9
(Figure 1). In MM, 55% of cells expressed CD105 at P0,
which increased to >95% at P3, remaining stable up to P9
(Figure 1a). However, in KM, the numbers of PLCSCs ex-
pressing CD105 at P0 were proportionally lower (40%),
and decreased to 18% at P3 (Figure 1b); between P4 and
P9, CD105 was expressed in an average 15% of PLCSCs
cultured in KM (Figure 1b). CD34 expression was seen
only in PLCSCs cultured in MM (Figure 1a). Expression at
P0 averaged 47%, but decreased rapidly during culture and
subsequent passaging.
This apparent heterogeneity within PLCSCs in differ-
ent media was further assessed by using a panel of cell-
surface markers (CSMs). Markers included the ISCT cri-
teria for MSC, additional markers chosen based on their
inclusion as MSC markers in the literature, and control
markers for ocular surface epithelium (Table 1). Analysis
of PLCSCs cultured in MM conformed to the ISCT
CSM criteria for MSCs. At P3, ≥95% of cells were posi-
tive for CD73, CD90, and CD105 and were negative
(≤2%) for CD11b, CD19, CD34, CD45, and HLA-DR. In
contrast, PLCSCs cultured in KM did not conform to
the ISCT criteria; The cells did not meet the positive
threshold values (≥95%) for CD73 and CD105, with
CD105 expressed only in an average 21% of PLCSCs,
compared with 97% for cells cultured in MM. Further
differences were found in marker expression between
cells cultured in the different media; PLCSCs cultured in
KM showed reduced proportions of ABCG2, CD13,
CD49e, HLA-ABC, and vimentin compared with cells
grown in MM. PLCSCs cultured in KM and MM did
not display any detectable levels of CK3, CK14, or CK19,
indicating no epithelial contamination.
To investigate the heterogeneity of PLCSCs further,
cells were cultured in MM and sorted on the basis oftheir respective CD34 and CD105 positivity. Three sub-
populations were isolated: CD34+CD105+, referred to as
subpopulation A; CD34-CD105+ (subpopulation B); and
CD34-CD105- (subpopulation C). Subpopulations cul-
tured in MM for a further three passages after isolation
were analyzed for the panel of CSM previously described
(Table 1). Individually, isolated cell subpopulations did
not conform to the ISCT CSM criteria. Although ini-
tially FACS isolated for CD34, after subsequent culture,
subpopulation A no longer contained CD34+ cells, and
the percentage of CD105+ cells had decreased to about
70%, falling below the ISCT positive threshold. Subpop-
ulation A contained greater numbers of cells expressing
HLA ABC, CD13, and CD49e, when compared with
subpopulations B and C, and were the only subpopula-
tion to possess ABCG2-, CD45-, and CD271-positive
cells. Subpopulation B remained CD34-, and CD105
positivity had decreased to 50%. Subpopulation C also
Table 1 Cell-surface marker profiling of PLCSCs and isolated subpopulations for ISCT criteria and additional markers
Cell-surface
markers
Mean % of positive cells cultured in Mean % of positive cells in subpopulation
MM KM A B C
ISCT Ppsitive criteria (≥95%)1
CD73 97.13 ± 0.81 ✓ 82.47 ± 2.73 ✕ 97.13 ± 0.81 ✓ 64.00 ± 4.00 ✕ 73.00 ± 3.00 ✕
CD90 98.13 ± 2.71 ✓ 99.97 ± 0.06 ✓ 99.47 ± 0.40 ✓ 99.97 ± 0.06 ✓ 97.67 ± 1.53 ✓
CD105 96.67 ± 1.53 ✓ 21.33 ± 2.08 ✕ 72.00 ± 6.00 ✕ 50.00 ± 10.00 ✕ 46.67 ± 20.82 ✕
ISCT negative criteria (<2%)
CD11b - ✓ - ✓ - ✓ - ✓ - ✓
CD19 - ✓ 0.54 ± 0.42 ✓ - ✓ 0.54 ± 0.42 ✓ - ✓
CD34 - ✓ - ✓ - ✓ - ✓ - ✓
CD45 - ✓ 1.80 ±0.26 ✓ 4.00 ± 2.00 ✕ - ✓ - ✓
HLA DP,DQ,DR - ✓ - ✓ - ✓ - ✓ - ✓
Additional Markers
ABCG2 2.05 ± 1.69 0.53 ± 0.04 10.00 ± 2.00 - -
CD13 56.67 ± 28.87 43.00 ± 1.00 70.00 ± 17.32 2.20 ± 0.20 3.27 ± 0.25
CD29 97.93 ± 2.55 97.23 ± 2.66 97.93 ± 2.55 96.90 ± 2.15 96.23 ± 1.33
CD44 97.00 ± 1.00 90.33 ± 0.58 96.00 ± 2.00 99.33 ± 0.58 99.00 ± 1.00
CD49e 77.00 ± 1.00 50.00 ± 5.00 59.07 ± 12.18 48.33 ± 1.53 30.00 ± 10.00
CD49f - - - - -
CD104 - - - - -
CD106 2.60 ± 0.26 0.6 ± 0.26 - 1.50 ± 0.46 1.30 ± 0.03
CD133 0.88 ± 0.15 0.59 ±0.09 0.88 ± 0.15 0.59 ± 0.09 0.66 ± 0.15
CD271 - 0.56 ±0.48 4.80 ± 1.85 - -
HLA ABC 97.90 ± 1.14 84.00 ± 1.00 42.00 ± 3.00 7.00 ± 2.00 4.00 ± 1.00
Stro-1 0.56 ± 0.27 0.47 ± 0.41 0.56 ± 0.27 - -
Vimentin 17.67 ± 2.52 8.00 ±1.00 13.33 ± 5.77 14.00 ± 2.00 10.00 ± 2.00
Control markers
CK 3/12 0.54 ± 0.23 - 0.60 ± 0.23 - -
CK 14 0.63 ± 0.21 - 0.81 ± 0.21 - -
CK 19 0.78 ± 0.29 - 0.72 ± 0.29 - -
PLCSCs cultured in MM and KM were analyzed for cell-surface markers at P3. Subpopulations (A: CD34+CD105+, B: CD34-CD105+, C: CD34-CD105-) were analyzed
after cell sorting and culture in MM up to P3. ✓denotes that the cells have fulfilled the ISCT criteria, ✓denotes that the cells did not conform to the ISCT criteria.
Values of ≤0.5% are denoted by dash (−). Values are represented by mean standard deviation (in brackets). Flow cytometry was performed on three separate
donor-cell populations.
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expression in an average of 47% of cells. Subpopulations
A, B, and C did not display any detectable levels of CK3,
CK14, or CK19, indicating no epithelial contamination.
Mesenchymal lineage differentiation potential
The ability of PLCSCs to differentiate into adipogenic,
osteogenic, and chondrogenic lineages was assessed in
both KM and MM (Figure 2). PLCSCs differentiated into
all three lineages when cultured in MM; however, they
demonstrated negligible differentiation potential when
cultured in KM. In adipogenic MM cultures, Oil Red O-
stained fat vacuoles were observed throughout but were
not present in stimulated KM and negative controls.Adipogenic genes were significantly upregulated when
stimulated in MM cultures, with increases in the relative
transcription of PPARG (10-fold change (fc)), PLIN
(4-fc), and FASN (4-fc), when compared with unstimu-
lated controls. No upregulation of adipogenic genes was
seen in cells differentiated in KM cultures. Chondrogene-
sis was observed with Alcian blue staining of glycosamino-
glycans. Deep staining of chondrogenic nodules can be
seen in cultures cultured in MM, whereas only light stain-
ing was seen in KM cultures. Figure 2k and 2n show high-
magnification images of individual chondrogenic nodules;
MM cultures showed nodules, such as these, across the
plate, but in KM, few nodules were seen. Chondrogenic
genes were also seen to be upregulated in stimulated MM,
Figure 2 (See legend on next page.)
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Figure 2 Effect of culture medium on the mesenchymal differentiation potential of PLCSCs. PLCSCs were cultured in KM or MM and put
through adipogenic, chondrogenic, and osteogenic differentiation protocols, and comparative qPCR analysis (a through i) and histologic staining
(j through o) were performed. Gene expression and staining for adipogenesis (a, FASN, d, PLIN;, g, PPARG, j and m, Oil Red O staining);
chondrogenesis (b, ACAN, e, COMP, h, SOX9, k and n, Alcian blue staining); osteogenesis (c, BMP4, f, BMP6, I, OPG, l and o, Alizarin red staining).
Values represented as mean ± SD, experiment repeated in triplicate, each with n = 3. P values for gene expression are indicated, and statistically
significant values are represented (*P < 0.01; **P < 0.001). Experiment was repeated in triplicate. Positive adipogenic, chondrogenic, and
osteogenic staining are represented by the presence of lipids (red), glycosaminoglycans (blue), and extracellular calcium deposits (red),
respectively. Magnification, 400×.
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compared with KM. The SOX9 gene showed no significant
upregulation in any medium. COMP was the only gene
upregulated in chondrogenic KM cultures (7-fc). Osteo-
genic differentiation was shown by Alizarin red staining of
calcium deposition in stimulated MM but not in KM.
Figure 2l and 2o show high-magnification images of an in-
dividual bone nodule in MM, but no staining was seen
in KM. Bone nodules were numerous across the MM
cultures. Significant upregulation of BMP4 (40-fc), BMP6
(13-fc), and OPG (9-fc) also occurred in stimulated MM,
compared with controls. Stimulated KM showed only small
upregulation of BMP6 compared with controls.
The mesenchymal differentiation potential of the dif-
ferent subpopulations also was assessed (Figure 3). Sub-
population A demonstrated significant upregulation of
the PLIN (6-fc) gene but not PPARG and FASN. Subpop-
ulation B showed general upregulation of all adipogenic
genes, although only PLIN (4-fc) was statistically signifi-
cant. PLIN (4-fc) was also significantly upregulated in
subpopulation C, whereas PPARG was downregulated,
and FASN was not significant with respect to the un-
stimulated control. Upregulation of the chondrogenic
genes ACAN (300-fc), COMP (7-fc), and SOX9 (1.5-fc)
was seen in subpopulation A, whereas only COMP (8-fc)
was significantly upregulated in subpopulation B. ACAN
(14-fc) and COMP (5-fc) were both upregulated in sub-
population C. Subpopulation A demonstrated significant
upregulation of the osteogenic genes BMP4 (110-fc),
BMP6 (34-fc), and OPG (1441-fc) compared with un-
stimulated control. Both subpopulations B and C showed
little significant change in osteogenic genes.
Mesenchymal-epithelial transdifferentiation
PLCSCs were put through the procedure for epithelial
differentiation (Figure 4) and subsequently analyzed by
using flow cytometry for CK19 and CK3, markers of
progenitor and differentiated corneal epithelium, re-
spectively. PLCSCs expressed CK 19 in 7% and CK3 in
22.8% of cells. In an attempt to improve the yield/purity
of epithelium produced by differentiation, PLCSC subpop-
ulations were also analyzed for CK3 and CK19 (Figure 4).
Subpopulation A showed 59% expression of CK3, the ter-
minally differentiated marker, and 43% of the progenitormarker CK19, at day 14 of differentiation. Subpopulation
B showed 25% expression of CK3 and 14% of CK19. Sub-
population C expressed CK3 and CK19 at low levels of
2.7% and 3.09% of cells, respectively. No coexpression of
CK3 and CK19 was observed on differentiated cells (data
not shown). In addition to marker expression, cell morph-
ology changed, with an increase in adherent spherical
cells, the prevalence of which correlated with increased
numbers of cells expressing epithelial markers.
Gene expression for epithelial progenitors (HES1,
FRZB1, DCT, SOD2, ABCG2, CDH1, and KRT19) and
terminally differentiated epithelial cells (DSG3, KRT3,
KRT12, and KRT24) was assessed after epithelial differen-
tiation of the three subpopulations (Figure 5). PLCSCs
showed a significant 5.5-fold upregulation of the HES1
gene, but not of any other progenitor or terminally differ-
entiated genes. In contrast, subpopulation A showed in-
creased expression for all corneal epithelial progenitor
genes, with the exception of KRT19. FRZB1 showed a 35-
fold increase, and HES1, a 21-fold increase compared with
control. Genes indicative of terminal differentiated corneal
epithelium were also significantly upregulated compared
with control, with the largest increase in DSG3, with a 12-
fold expression. Subpopulation B showed no upregulation
of the progenitor genes but did show a threefold
upregulation of KRT3 and KRT12 for terminal differenti-
ation markers. Subpopulation C showed no upregulation
of either the progenitor or terminal-differentiation genes.
Discussion
PLCSCs are a heterogeneous population of cells,
containing several subpopulations, including the classic
CD34+ keratocyte [66]. Previously, PLCSCs were charac-
terized as CD34, ALDH, and keratocan positive, before
culture (Branch et al., 2012). The various subpopulations
can be selectively isolated by using different culture
media or by marker-specific isolation. Media selection of
PLCSCs may have implications for the conventional un-
derstanding of keratocyte characteristics. Historically, re-
tention and expansion of keratocyte numbers with a
CD34+ phenotype in vitro has been difficult. Conven-
tionally, the presence of serum or, more specifically,
growth factors such as TGF-β1 [67,68] are reported to
cause a fibroblastic or myofibroblastic phenotype,
Figure 3 Mesenchymal differentiation potential of subpopulations of PLCSCs. PLCSCs were sorted into subpopulations (A, CD34+CD105+; B,
CD34-CD105+; C, CD34-CD105-) and put through adipogenic, chondrogenic, and osteogenic differentiation protocols and comparative qPCR
analysis (a through i) were performed. Gene expression for adipogenesis (a, FASN; d, PLIN; g PPARG; chondrogenesis (b, ACAN; e, COMP; h, SOX9);
osteogenesis (c, BMP4; f, BMP6; I, OPG). Values are represented as mean ± SD, and experiments were repeated in triplicate, each with n = 3.
P values for gene expression are indicated, and statistically significant values are represented (*P < 0.01; **P < 0.001).
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markers such as αSMA [68,69] and CD90 [70], along
with the loss of keratocyte markers [6,71]. Some mitogen
is essential for keratocyte growth, whether low serum or
a serum substitute (such as defined growth factor com-
binations or bovine pituitary extract) is required for pro-
liferation. Culture in low-mitogen or low-serum media
has occasionally been reported to preserve keratocyte
phenotype while promoting proliferation [18,67]; how-
ever, a new standard medium has yet to be established
for this purpose. Notably, Funderburgh et al. [18,24] use
low-serum or serum-free medium and described the
multipotency of keratocytes and their precursors. Several
other groups reported retention of keratocyte and stem
cell phenotypes when culturing in DMEM/F12 [72-74]
or DMEM/MCDB-201 [24,75] rather than DMEM,although factors such as low serum or addition of
growth factors also cause variation.
Although keratocytes are routinely cultured in the clas-
sic DMEM-based medium, supplemented with 10% FBS
and antibiotics [17,46,69,71,76,77] (referred to here as
KM), our findings suggest that DMEM is a poor medium
for the culture of keratocytes. Herein, we show that this
medium causes a rapid loss of several markers, including
CD105 and the keratocyte marker CD34. We recently
characterized PLCSCs as MSC [15] (for which CD105 is a
key marker) by using an M199-based medium (MM).
However, when cultured in KM, PLCSCs do not conform
to the MSC criteria, predominantly because of a loss of
the CD105 marker. CD105 downregulation is associated
with MSC differentiation [78,79], and the loss of CD105
observed in PLCSCs cultured in KM, therefore, indicates
Figure 4 Epithelial transdifferentiation of PLCSCs and subpopulations A, B, and C. Epithelial differentiation of the entire PLCSC population
(a, e, i) and subpopulations A (b, f, j), B (c, g, k), and C (d, h, l) was assessed. Analysis of percentage of cells expressing the differentiated
epithelial marker CK3 (a, b, c, d) and the epithelial progenitor marker CK19 (e, f, g, h) was performed with flow cytometry on three separate donor
cell populations. Images of cell morphology were taken after epithelial transdifferentiation (i, j, k, l). Magnification at 200×; scale bar, 46 μm.
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a decrease in multipotent differentiation potential when
PLCSCs are cultured in KM. This loss of progenitor char-
acteristics may explain why literature often describes
keratocytes cultured in KM as activated, fibroblastic, and
subsequently myofibroblastic in nature, but often does not
discuss their progenitor properties [68,69,80].
The results of this study may also suggest that CD34
is a marker of corneal stromal progenitor cells similar
to those described by Funderburgh et al. [18]. When
cultured in MM, PLCSCs demonstrated greater reten-
tion of CD34 and CD105 markers at early passage, and
conformed to the MSC criteria after subsequent pas-
sages. As PLCSCs cultured in MM have already been
shown to conform to the ISCT’s established MSCcriteria [15], this medium is useful for studying their
multipotent associated characteristics.
By examining CSM expression, we have been able to in-
vestigate PLCSC heterogeneity further. We isolated and
characterized three subpopulations of PLCSCs on the
basis of CD34 and CD105 expression. Although no sub-
population conformed entirely to the ISCT guidelines for
MSC characterization, the individual profiles of markers
are not greatly dissimilar from MSC, indicating it is likely
that they share a common, mesenchymal origin. Similar to
PLCSCs cultured in MM, cells from subpopulation A, ori-
ginally positive for CD34, give rise to cultures that lose ob-
servable CD34 expression. Our previous work indicated
that this loss is due to slow-cycling CD34+ cells and the
rapid proliferation of their progeny [15]. Although
Figure 5 Changes in gene expression after epithelial transdifferentiation of subpopulations A, B, C, and PLCSC populations.
Comparative qPCR was performed for epithelial progenitor genes (a, b, c, d, HES1, FRZ1, DCT, SOD2, ABCG2, CDH1, and KRT19) and terminally
differentiated epithelial genes (e, f, g, h DSG3, KRT3, KRT12, KRT24). All fold changes are expressed relative to control gene 18S. Inset images
show data on a reduced scale. Values are represented as mean ± SD. The experiment was repeated in triplicate, each with n = 3. Statistical
significance is represented as *P ≤ 0.01, **P ≤ 0.001, ***P ≤ 0.0001.
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contained a small number of CD45+ Cells. Despite this,
subpopulation A did not produce hematopoietic colonies
in specific HSC culture conditions (data not shown). Sub-
population A expressed stem cell markers, ABCG2 [81]
and CD271 [82], not found in the other two subpopula-
tions. CD271 is a known marker for osteogenic differenti-
ation [82] and was expressed only by subpopulation A, the
only group to demonstrate significant osteogenic differen-
tiation. Subpopulations A, B, and C were also distin-
guished by the proportion of cells expressing CD13 and
HLA ABC. Subpopulations B and C displayed similar
marker profiles on further culture and reanalysis after
sorting. The proportion of cells expressing CD105 de-
creased in subpopulation B, after isolation. However,
when sorted for absence of CD105, subpopulation C
consistently regained CD105 expression with further
culture, reaching levels equivalent to subpopulation B.
This contrasts with the irreversible loss of CD34 expres-
sion in subpopulation A. Subpopulation B possessed a
greater capacity for differentiation than A with regard
to adipogenesis; however, subpopulation A had the abil-
ity to differentiate into all three lineages, although
adipogenesis was poor. Subpopulation C did not exhibit
any trilineage potential.
Based on marker profiles and differentiation potential,
our evidence suggests subpopulation A to be the most
stemlike, and C, the most differentiated. However, iso-
lated subpopulation C quickly reverts to a similarphenotype to subpopulation B, which suggests that the
main difference lies in the presence or absence of CD34.
Our results indicate that PLCSCs cultured in MM share
similar characteristics with subpopulation A, whereas
PLCSCs cultured in KM are phenotypically most similar
to subpopulation C. With the appropriate optimization
and development, culturing heterogeneous PLCSC pop-
ulations in defined medium could be used to select a
specific subpopulation of cells, with minimal contamin-
ation from other cell populations. This has considerable
potential benefits, most significantly for clinical isolation
and preparation.
The presence of so-called hematopoietic markers, such as
CD34, on keratocytes [38,39,83] and other MSC-like cells
[49,50,84-88] is not uncommon. CD34+ PLCSCs appear
similar to the CD34+ multipotent progenitors found in fetal
liver, which are able to produce mesenchymal lineages and
biliary epithelium [49,51,89]. Both fetal liver and CD34+
PLCSCs generated CK19+ progenitors of biliary and cor-
neal epithelium, respectively. MSC-like cells with these
markers are often described as possessing potent stem
cell properties, including the capacity to produce MSC
[15,49,50,84-88] and epithelium [50,85]. MSC-epithelial
transdifferentiation has been demonstrated in several stud-
ies [52-55]. CD34+ progenitors of keratinocytes in the skin
are well documented [56-58]. We previously found CD34+
keratocytes that coexpressed the corneal epithelial marker
CK3, indicating the potential for transdifferentiation
from mesenchyme to epithelial lineages [59]. This
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potential epithelial differentiation. This led to the re-
sultant sorting and epithelial transdifferentiation of the
three subpopulations with subsequent analysis at the
gene and protein levels. Transdifferentiation of the dif-
ferent subpopulations revealed a varied capacity for the
production of corneal epithelium. Subpopulation A, ori-
ginally isolated as CD34+, demonstrated a rounded
morphology, similar to that of corneal epithelium, after
differentiation medium was applied. This subpopulation
contained cells expressing CK19, an epithelial progeni-
tor marker, and cells expressing CK3, a marker for ter-
minally differentiated epithelial cells, indicating the
presence of a mixed population of differentiated and
undifferentiated corneal epithelium [13,90,91]. On fur-
ther analysis, the cells of subpopulation A demonstrated
an upregulation of epithelial progenitor genes (HES1,
FRZB1, DCT, SOD2, ABCG2, CDH1, and KRT19) found
in limbal crypt epithelium [14] and differentiated cor-
neal epithelium genes (desmoglein 3, KRT3, KRT12, and
KRT24) [13,14,90,91]. These markers were selected
based on our recent body of evidence from transcriptomic
characterization of corneal epithelial stems cells in
the limbal epithelial crypts [14]. A comparatively lower
percentage of cells from subpopulation B showed
transdifferentiation into corneal epithelium, based on
morphology and CK3 and CK19 expression, and, as a
result, it was difficult to discern whether upregulation
of corneal epithelial genes occurred, although CK3 and
CK12 still demonstrated a significant increase in ex-
pression. Subpopulation C showed very little potential
to undergo epithelial transdifferentiation, as assessed by
gene, protein, and morphologic analysis.
Conclusions
Our findings demonstrate that CD34+ PLCSCs have
multipotent progenitor capacity, which includes differen-
tiation into both mesenchymal and corneal epithelial
phenotypes. This evidence challenges current percep-
tions of the role of the keratocyte, which may possess
significant potential for corneal regeneration. However,
current culture conditions are suboptimal for the expan-
sion of these stemlike cells, and modest changes in for-
mulation of culture medium can affect stemness. This
development complements a growing body of literature
confirming the presence and usefulness of stromal stem
cells within the cornea [16-18,46]. Although novel with
respect to the cornea, our findings are supported by
similar observations in other parts of the body.
It is tempting to speculate that these corneal stromal
stem cells contribute to the regeneration of the corneal
epithelium in vivo. These cells are present in the limbal
region, a proven site of epithelial stem cell activity
[13,92], where the Bowman membrane, which normallyfunctions as a barrier between epithelium and stroma, is
absent [93,94]. Nevertheless, the CD34+ corneal stromal
stem cells represent an exciting prospect for ocular tis-
sue engineering and regenerative medicine. Specifically,
they may provide an alternate cell source for the treat-
ment of limbal stem cell deficiency.
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